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Hereditary hemochromatosis (HH) is a common autosomal-recessive disorder associated with pathogenicHFE variants, most commonly
those resulting in p.Cys282Tyr and p.His63Asp. Recommendations on returning incidental findings of HFE variants in individuals un-
dergoing genome-scale sequencing should be informed by penetrance estimates of HH in unselected samples. We used the eMERGE
Network, a multicenter cohort with genotype data linked to electronic medical records, to estimate the diagnostic rate and clinical pene-
trance of HH in 98 individuals homozygous for the variant coding for HFE p.Cys282Tyr and 397 compound heterozygotes with variants
resulting in p.[His63Asp];[Cys282Tyr]. The diagnostic rate of HH in males was 24.4% for p.Cys282Tyr homozygotes and 3.5% for com-
pound heterozygotes (p < 0.001); in females, it was 14.0% for p.Cys282Tyr homozygotes and 2.3% for compound heterozygotes (p <
0.001). Only males showed differences across genotypes in transferrin saturation levels (100% of homozygotes versus 37.5% of com-
pound heterozygotes with transferrin saturation > 50%; p ¼ 0.003), serum ferritin levels (77.8% versus 33.3% with serum ferritin >
300 ng/ml; p ¼ 0.006), and diabetes (44.7% versus 28.0%; p ¼ 0.03). No differences were found in the prevalence of heart disease,
arthritis, or liver disease, except for the rate of liver biopsy (10.9% versus 1.8% [p ¼ 0.013] in males; 9.1% versus 2% [p ¼ 0.035] in
females). Given the higher rate of HH diagnosis than in prior studies, the high penetrance of iron overload, and the frequency of
at-risk genotypes, in addition to other suggested actionable adult-onset genetic conditions, opportunistic screening should be consid-
ered for p.[Cys282Tyr];[Cys282Tyr] individuals with existing genomic data.Introduction
Hereditary hemochromatosis (HH [MIM: 235200]) is the
most common genetic disorder identified in those of Euro-
pean ancestry and is characterized by an inappropriate
increased absorption of dietary iron. If left untreated, HH
can lead to morbidity and mortality, including liver
cirrhosis, hepatocellular carcinoma, diabetes, and heart dis-
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for 80%–85% of individuals with HH.3,4 A more common
HH variant (MAF ¼ 17% in the 1000 Genomes European
population) is c.187C>G, which results in the substitution
of aspartate for histidine at amino acid position 63 (p.Hi-
s63Asp); this variant causes a milder degree of iron overab-
sorption and is most relevant to disease when paired with
the allele for p.Cys282Tyr in compound heterozygotes.3
To improve clarity, we will henceforth use the protein
change as a surrogate for genotype. Several other hemo-
chromatosis-associated pathogenic variants in HFE have
been described, as well as variants in genes other than
HFE (e.g., HJV [MIM: 608374], HAMP [MIM: 606464], and
TFR2 [MIM: 604720]), but these are rare.5,6
Estimates of penetrance for HH-related variants vary
widely depending on the signs or symptoms used in dis-
ease assessment.7 For instance, in p.Cys282Tyr homozy-
gotes from a racially diverse cohort, the prevalence of
elevated serum ferritin (>300 ng/ml for males and
>200 ng/ml for females) and transferrin saturation levels
(>50% in men and >45% in women) was 40%–60% in
females and 75%–100% in males.8–12 In contrast, in
another cohort of northern European descent, the preva-
lence of iron-overload-related disease (defined as liver
fibrosis, elevated transaminases, hepatocellular carcinoma,
arthropathy, or physician-diagnosed HH in individuals
with high ferritin or transferrin saturation) in p.Cys282Tyr
homozygotes was 1.2% (95% confidence interval [CI] ¼
0.03–6.5) in females and 28.4% (95% CI ¼ 18.8–40.2) in
males.13 The lower clinical penetrance in women has
been suggested to result from iron loss through menstrual
bleeding and childbirth, although evidence is lacking.5
These variations in estimates of penetrance have resulted
in insufficient evidence for confidently projecting the
impact, or estimating the benefit, of widespread genetic
screening for HH.14 Whereas newborn screening for HH
has not been adopted because of its adult onset and incom-
plete penetrance,15 the utility of using existing genetic data
for screening for HH risk has not been carefully addressed.
The American College of Medical Genetics and Genomics
(ACMG) does not currently include HH among the
gene-disease pairs it recommends evaluating and returning
as incidental findings for genome-scale sequencing,16
although other recommendations have been proposed.17
Development of such recommendations would be
informed by the penetrance and rate of diagnosis of HH
in unselected samples.
The primary objective of this study was to determine the
frequency of diagnosis of HFE-related HH and to estimate
the penetrance of clinically related variables in the Elec-
tronic Medical Records and Genomics (eMERGE) Network,
a national consortium organized by the National Human
Genome Research Institute to develop, disseminate, and
apply approaches to research by combining DNA bio-
repositories with electronic-medical-record systems for
high-throughput genetic research. The network’s goals
include returning genomic testing results to individuals
in a clinical setting.18,19 This cohort was generally ascer-The Americtained independently of HH diagnosis. By identifying all
participants carrying the p.[Cys282Tyr];[Cys282Tyr] and
p.[Cys282Tyr];[His63Asp] genotypes and reviewing their
medical records, we obtained a minimally biased estimate
of general population frequency of HH diagnosis and
related signs in those at genetic risk. A secondary objective
of this study was to serve as a proof of principle to deter-
mine the efficacy of this multicenter consortium to esti-
mate the penetrance of common phenotypes associated
with relatively uncommon genetic variants.Subjects and Methods
eMERGE Network Participants
The eMERGE Network is a consortium of seven adult and two pe-
diatric US cohorts with DNA biorepositories linked to electronic-
medical-record data for large-scale, high-throughput genetic
research.18–20 Participating sites for the adult cohort included
the following: (1) Group Health Cooperative and University of
Washington, Seattle, WA; (2) Marshfield Clinic, Marshfield, WI;
(3) Mayo Clinic, Rochester, MN; (4) Northwestern University,
Evanston, IL; (5) Vanderbilt University, Nashville, TN; (6) Icahn
School of Medicine at Mount Sinai, New York, NY; and (7) Gei-
singer Health System, Danville, PA.20 Northwestern’s cohort
included participants ascertained from a liver clinic; these partici-
pants were excluded from the calculation of HH penetrance. The
Geisinger cohort included participants from a weight-loss and
gastric-bypass clinic, which included liver biopsy in its routine
care. These individuals were excluded from the calculation of
the rate of liver biopsy. Because MAFs for rs1800562 and
rs1799945 are more common in individuals of European ancestry
and HH is most common in this ancestry, we limited our analysis
to this population. The human-subjects procedures that we fol-
lowedwere in accordance with the ethical standards of the respon-
sible committee on human experimentation at each institution,
and proper informed consent was obtained from each participant.
Genotyping and Imputation
We selected participants who were either homozygotes for
rs1800562 (p.Cys282Tyr) or compound heterozygotes for both
rs1800562 and rs1799945 (p.His63Asp). Genotypes for these
HFE variants were either directly measured or imputed for all sites.
Genotyping, quality-control, and imputation procedures for the
eMERGE Network have been previously described.21,22 Partici-
pants from eMERGE phase I were genotyped on the Illumina Hu-
man 660W-Quadv1_A or Illumina Human 1 M-Duo platform.
Genotypes for both platforms were called at the Center for In-
herited Disease Research and the Broad Institute with BeadStudio
version 3.3.7 and Gentrain version 1.0. eMERGE phase II includes
genotype data from a variety of platforms: Illumina 550, 610Q,
660W Quad-v1, 1M-Duo, 1M-Quad, OmniExpress, Metabochip,
OMNI-1, OMNI-5, and Affymetrix 6.0.19
We performed imputation with a reference panel from the
October 2011 release of the 1000 Genomes Project by using
BEAGLE version 3.3.1. Both SNPs were genotyped on the Illumina
Metabochip and 1M-Duo, rs1800562 was genotyped on the Illu-
mina 660W, and rs1799945 was genotyped on the Illumina
OMNI. For all other genotyping platforms, the imputed genotypes
for the SNPs were used. Directly genotyped SNPs and imputed
SNPs are summarized by site in Table S1.an Journal of Human Genetics 97, 512–520, October 1, 2015 513
Table 1. Site Distribution and Demographic Characteristics of
Individuals by Genotype
p.[Cys282Tyr];
[Cys282Tyr]
p.[Cys282Tyr];
[His63Asp] Total
No. of Samples per Site
Geisinger Health
System
12 61 73
Group Health
Cooperative
and UW
12 48 60
Marshfield Clinic 15 52 67
Mayo Clinic 30 117 147
Icahn School of
Medicine at
Mount Sinai
1 13 14
Northwestern
University
16 61 77
Vanderbilt
University
20 80 100
Total 106 432 538
Sample Descriptions
Proportion of
males
45.28%
(48/106)
44.91%
(194/432)
44.98%
(242/538)
Age at time of
abstraction
67.5 5 17.1 66.1 5 15.5 66.4 5 15.8
Age at diagnosis
of HH
61.5 5 14.6 56.3 5 7.2 59.6 5 12.5
Race
White 92.45%
(98/106)
91.90%
(397/432)
92.00%
(495/538)
African American 0% (0/106) 0.46%
(2/432)
0.37%
(2/538)
Other, unknown,
or missing
7.55%
(8/106)
7.64%
(33/432)
7.62%
(41/538)
For individuals with the HFE genotypes resulting in p.[Cys282Tyr];[Cys282Tyr]
or p.[Cys282Tyr];[His63Asp] and available linked data from electronic medical
records. Sex (males) and race data are represented as a percentage, and the
proportion of affected individuals is in parentheses. Age is represented as the
mean in years 5 SD. Only the 495 individuals of European ancestry were
included in the analysis. The following abbreviation is used: UW, University
of Washington.We genotyped the two HFE SNPs with the TaqMan at Geisinger
Health System in a subset of 179 eMERGE participants to evaluate
the concordance between the imputed genotypes and TaqMan ge-
notypes. The concordance between TaqMan and imputed geno-
types was 98.9% for rs1800562 and 98.3% for rs1799945.Clinical Data
A chart-abstraction form was designed in accordance with pub-
lished recommendations.23 This common collection instrument
was developed with a Research Electronic Data Capture form
shared between all sites.24 Electronic and paper medical records
were reviewed. Demographic data were extracted from existing
eMERGE databases. The information extracted from medical re-
cords included medical history of hemochromatosis or iron-over-
load-related conditions, iron-related laboratory studies, imaging
studies, and physical findings consistent with HH (Table S2).514 The American Journal of Human Genetics 97, 512–520, OctoberIn the absence of secondary iron-overload state, HH diagnosis
was based on the physician annotation of HH in the medical re-
cords, including a recent clinical note, problem list, or ICD-9
(International Code of Diseases, Ninth Revision) codes 275.01,
275.02, or 275.03. We used a broad definition of liver disease
and included individuals with liver cirrhosis, other chronic hepat-
ic phenotypes (i.e., alcoholic liver disease, chronic viral hepatitis,
fatty liver disease, or non-specific liver enzyme elevation), hepato-
cellular carcinoma, hepatomegaly, ascites, history of liver biopsy,
and elevated liver function. A manual of procedures was written
for the data abstractors’ training and reference, and common ex-
amples of situations encountered by abstractors were discussed
before the final form was distributed. A pilot test form was de-
signed to ensure the reliability and validity of the data-collection
instruments. Monthly teleconferences with all sites took place
during the form-development and abstraction phases of the proj-
ect. These calls addressed questions about coding to ensure consis-
tency, accounting for differences in medical-record structures
(including different measuring units in the laboratories), and dis-
parities in the availability of certain data.
Analysis
All statistical analyses and penetrance calculations were done in R
statistical computing software. We stratified by sex and compared
p.Cys282Tyr homozygous to p.[Cys282Tyr];[His63Asp] com-
pound-heterozygous genotypes. Differences in the rates of HH
diagnosis between genotypes were tested with a Chi-square test.
Other HH-related phenotypes and related clinical and laboratory
values between genotypes were tested with Fisher’s exact test
because of small sample sizes for some of the variables. Because
the tests are correlated rather than independent, they were not
adjusted for multiple comparisons.Results
In the cohort of approximately 39,000 individuals with ge-
notype data available in the eMERGE Network, we identi-
fied 618 individuals with the p.Cys282Tyr homozygous
or p.[Cys282Tyr];[His63Asp] compound-heterozygous ge-
notype; of these, 538 individuals had corresponding data
from electronic medical records. Demographic characteris-
tics of these individuals are summarized in Table 1. The
mean age of participants was 66.4 years (515.8), and
the average age at HH diagnosis was 59.6 years (512.5).
The subsequent analysis included a total of 495 individuals
of European ancestry (92%), 98 with the p.[Cys282Tyr];
[Cys282Tyr] and 397 with the p.[Cys282Tyr];[His63Asp]
genotype. We excluded six Northwestern participants
who were ascertained from a liver clinic from the calcula-
tion of HH penetrance; 95 p.Cys282Tyr homozygotes
and 392 compound heterozygotes with information on
HH diagnosis were included in this analysis.
The frequency of HH diagnosis was 24.4% in male
p.Cys282Tyr homozygotes and 3.5% inmale p.[Cys282Tyr];
[His63Asp] compound heterozygotes (p < 0.001), whereas
the diagnostic rate was 14.0% in female p.Cys282Tyr ho-
mozygotes and 2.3% in female compound heterozygotes
(p < 0.001). A summary of the differences in diagnostic
rate and relevant phenotypes of HH across genotypes is1, 2015
Table 2. Summary of Clinical Penetrance and Diagnostic Rate of HH
Male (n ¼ 222) Female (n ¼ 273)
p.[Cys282Tyr];
[Cys282Tyr]
(n ¼ 47)
p.[Cys282Tyr];
[His63Asp]
(n ¼ 175) p Value
p.[Cys282Tyr];
[Cys282Tyr]
(n ¼ 51)
p.[Cys282Tyr];
[His63Asp]
(n ¼ 222) p Value
Clinical
Diagnostic rate of HH 24.4% (11/45) 3.4% (6/174) <0.001 14.0% (7/50) 2.3% (5/218) <0.001
Liver disease 34.3% (12/35) 24.4% (29/119) 0.279 29.0% (9/31) 29.0% (42/145) 1
Liver biopsy (not incidental
to gastric bypass)
10.9% (5/46) 1.8% (3/166) 0.013 9.1% (4/44) 2.0% (4/205) 0.035
Liver cirrhosisa 4.5% (2/44) 4.8% (8/166) 1 2.5% (1/40) 4.9% (10/203) 0.697
Other chronic liver diseaseb 7.0% (3/43) 6.7% (11/164) 1 0% (0/41) 7.8% (16/205) 0.081
Hepatocellular carcinoma 0% (0/46) 0% (0/169) NA 0% (0/50) 0% (0/218) NA
Congestive heart failure 21.7% (10/46) 16.8% (29/173) 0.515 18.4% (9/49) 8.7% (19/219) 0.067
Cardiomyopathy 6.7% (3/45) 7.5% (13/174) 1 4.1% (2/49) 1.8% (4/218) 0.304
Diabetes 44.7% (21/47) 28.0% (49/175) 0.034 12.0% (6/50) 19.5% (43/220) 0.308
Arthritis 29.5% (13/44) 35.3% (61/173) 0.594 26.0% (13/50) 30.3% (66/218) 0.609
Hypogonadism 2.2% (1/45) 1.8% (3/167) 1 NA NA NA
Family History
Family history of HH 8.1% (3/37) 0% (0/157) 0.006 6.7% (3/45) 1.5% (3/199) 0.078
Medications
Over-the-counter
arthritis medications
17.0% (8/47) 20.0% (34/170) 0.835 24.0% (12/50) 24.2% (52/215) 1
Oral diabetes medications 27.7% (13/47) 18.6% (32/172) 0.221 7.8% (4/51) 16.0% (35/219) 0.184
Insulin 17.0% (8/47) 14.9% (26/174) 0.820 3.9% (2/51) 13.6% (30/220) 0.056
Physical Exam
Pain on palpation PIP
or MCP joints
6.5% (3/46) 3.0% (5/166) 0.375 7.1% (3/42) 3.0% (6/201) 0.190
Skin pigmentation 4.4% (2/45) 1.2% (2/167) 0.199 2.4% (1/42) 2.5% (5/201) 1
Hepatomegaly 2.2% (1/46) 3.6% (6/165) 1 0% (0/41) 2.5% (5/201) 0.592
Ascites 4.3% (2/46) 1.8% (3/167) 0.295 0% (0/42) 2.5% (5/201) 0.591
Testicular atrophy 2.2% (1/45) 0% (0/161) 0.218 NA NA NA
Laboratories
AST > 80 u/l 2.5% (1/40) 12.4% (19/153) 0.082 8.5% (4/47) 8.9% (17/191) 1
ALT > 110 u/l 0% (0/35) 7.5% (10/133) 0.124 5.1% (2/39) 8.2% (13/158) 0.740
Transferrin saturation > 50% 100% (9/9) 37.5% (6/16) 0.003 50.0% (4/8) 37.5% (15/40) 0.695
Ferritin > 200 ng/ml
(females); > 300 ng/ml (males)
77.8% (14/18) 33.3% (8/24) 0.006 30.8% (4/13) 30.2% (16/53) 1
Clinical features are arranged by genotype. The total number of individuals might vary for different variables as a result of missing or unavailable clinical data. Data
are represented as a percentage, and the proportion of affected individuals is in parentheses. Abbreviations are as follows: ALT, alanine aminotransferase; AST,
aspartate aminotransferase; HH, hereditary hemochromatosis; MCP, metacarpophalangeal; NA, not available; PIP, proximal interphalangeal.
aDiagnosed by notes and ICD-9 code 571.
bDiagnosed by notes, ICD-9 codes 571, 794.8, 790.4, and 790.6, and lab criteria (liver enzyme elevation for >6 months).shown in Table 2, and a comprehensive list of phenotypes
is shown in Table S3. The diagnostic rates by genotype and
study site are shown in Table S4. The Kaplan-Meier curve
(Figure 1) demonstrates the frequency of HH diagnoses
by age and sex for p.Cys282Tyr homozygotes andThe Americp.[Cys282Tyr];[His63Asp] compound heterozygotes
separately.
As expected, for many signs of HH, the penetrance was
higher in p.Cys282Tyr homozygotes than in p.[Cys282Tyr];
[His63Asp] compound heterozygotes, although some signsan Journal of Human Genetics 97, 512–520, October 1, 2015 515
Figure 1. Kaplan-Meier Curves of HH Diagnosis
Frequency of HH diagnosis by age and sex separately for HFE p.Cys282Tyr homozygotes and p.[Cys282Tyr];[His63Asp] compound het-
erozygotes. Each crosshair represents a new HH diagnosis.of HH did not differ by genotype. Iron studies were signif-
icantly different between genotypes in males only, where
transferrin saturation above 50%wasmore common in ho-
mozygotes than in compound heterozygotes (100% versus
37.5%; p ¼ 0.003), and serum ferritin higher than
300 ng/ml was more frequent in homozygotes (77.8%
versus 33.3%; p ¼ 0.006). No differences in iron studies
were found across genotypes in females.
The overall prevalence of liver disease in males was
34.3% in homozygotes and 24.4% in compound heterozy-
gotes (p ¼ 0.279), and in females the prevalence was 29%
for both genotypes. The rate of liver biopsy was also signif-
icantly different between homozygotes and compound
heterozygotes for males (10.9% versus 1.8%; p ¼ 0.013)
and females (9.1% versus 2%; p¼ 0.035). No significant ge-
notype differences were found for other liver phenotypes,
which included the presence of any liver disease, liver
cirrhosis, other chronic liver diseases, hepatocellular carci-
noma, elevated transaminases, or physical findings consis-
tent with liver disease (e.g., hepatomegaly or ascites).
Differences between genotypes were found in the pro-
portion of individuals with a history of phlebotomy in
males (19.6% in homozygotes versus 2.9% in compound
heterozygotes; p ¼ < 0.001) and females (8% versus
0.5%; p ¼ 0.005), as expected. Males, but not females,
had differences between genotypes in the rates of diabetes
(44.7% versus 28%; p ¼ 0.03) and family history of HH516 The American Journal of Human Genetics 97, 512–520, October(8.1% versus 0%; p ¼ 0.006), whereas females had geno-
type differences in the proportion of hand X-ray for evalu-
ation of arthritis (24.5% versus 11.5%; p ¼ 0.023). No
significant differences were found between genotypes for
either sex in the rates of congestive heart failure, cardiomy-
opathy, osteoarthritis, hypogonadism, history of alcohol
or tobacco abuse, use of over-the-counter medication for
arthritis, diabetes medication (including insulin), propor-
tion of individuals with imaging studies (e.g., abdominal
ultrasound or echocardiogram), presence of arthralgia,
pain on palpation of proximal interphalangeal or metacar-
pophalangeal joints, or skin hyperpigmentation.
In one of our study sites (Vanderbilt University), it was
noted that among 41 p.Cys282Tyr homozygotes, 7 (17%)
were receiving iron, and none of these individuals had a
diagnosis of HH. Out of these seven individuals, three
had iron labs tested: two had normal studies, and one un-
derwent Roux-en-Y gastric bypass surgery, after which iron
was prescribed (iron saturation was initially normal at 37%
but then jumped to 71% after 6 months of iron-replace-
ment therapy).Discussion
In this study, we estimated the diagnostic rate and clinical
penetrance of HH in p.Cys282Tyr homozygous and1, 2015
p.[Cys282Tyr];[His63Asp] compound-heterozygous indi-
viduals in the eMERGE Network. We found that among
p.Cys282Tyr homozygotes, 24% of male and 14% of fe-
male individuals carried a diagnosis of HH. These propor-
tions are higher than the diagnostic rate of 8.5% reported
previously in the literature for males and females with
this genotype.13 For compound heterozygotes, 3.4% of
males and 2.3% of females were diagnosed with HH. We
found that 100% of p.Cys282Tyr homozygotes had a trans-
ferrin saturation> 50%, and 78%had ferritin> 300 ng/ml,
whereas only 37% and 33% of p.[Cys282Tyr];[His63Asp]
heterozygotes met these transferrin and ferritin thresholds,
respectively. The biochemical penetrance (i.e., presence of
iron overload by transferrin saturation and serum ferritin
concentration only) was similar to estimates from previous
studies of large prospective cohorts.8,13,25
The overall prevalence of liver disease ranged from 24%
to 34%, higher than the 10% or lower reported for homo-
zygous males in prior studies.9,13,26,27 This might be due to
our broad definition of liver disease and the inability to
separate HH-related liver disease from other causes of liver
disease. The prevalence of liver cirrhosis in p.Cys282Tyr
homozygous males was 4.5%, consistent with previous
reports of 3.4%–5% in this population.27 The only liver-
related phenotype that significantly differed between ge-
notypes was the proportion of individuals who underwent
liver biopsy, which was higher for homozygous females
andmales than for compound heterozygotes. A hypothesis
for this difference is that the referral of individuals for liver
biopsy happened after a suspicion of hemochromatosis
was made on the basis of biochemical (i.e., abnormal
iron studies) rater than clinical abnormalities.
Finally, our study revealed thatmost ofwhat is considered
the extreme phenotype of hemochromatosis—which in-
cludes liver cirrhosis, hepatocellular carcinoma, and cardiac
phenotypes, specifically cardiomyopathies—doesnot differ
across genotypes, which is consistent with the fact that
these late manifestations are nowadays uncommon as a
consequenceofHHandcanbepreventedby the earlydetec-
tion and treatment of HHwith phlebotomy. The exception
to this was diabetes, a late HH complication that we found
more frequently among homozygous than among com-
pound-heterozygous males. Furthermore, early signs of he-
mochromatosis (e.g., fatigue, arthritis, and skin hyperpig-
mentation) did not significantly differ by genotype,
possibly because these signs are difficult to define, might
not be captured in the electronic health record, and occur
commonly in the population at large and thus limit power.
Finding a higher rate of diagnosis of HH in our study has
implications for the return of incidental genomic findings.
Currently, the return of pathogenic HFE variants to indi-
viduals who have genomic information available (oppor-
tunistic screening) is not yet recommended by the
ACMG.16 Although the adult onset and incomplete pene-
trance of HH might be inadequate to justify screening of
children14,15 and the ACMG currently does not recom-
mend directed HH testing unless an individual has ironThe Americoverload or a family history of HFE-associated HH, a lower
threshold of risk might be considered for opportunistic
screening of existing genomic data. New recommenda-
tions should address the effectiveness of opportunistic
screening and population screening for hemochromatosis
under this new evidence, as well as penetrance data from
other cohorts unselected for genetic phenotypes and
large-scale genetic data linked to medical-record informa-
tion. Moreover, with the decreasing cost of sequencing,
and the additive effectiveness of finding a predisposition
not only to hemochromatosis but also to cancer and to
other common diseases, the use of genomic tests (i.e.,
exome or genome sequencing) for newborn or adult
screening in the general population might be clinically
beneficial. This incorporation of genomic technologies
for screening purposes will need to be supported by studies
of cost effectiveness and outcomes research.
A second clinical implication results from the possibility
of preemptively identifying individuals with a high-risk
phenotype and currently receivingmedications that might
exacerbate a condition or make it clinically evident. A sin-
gle eMERGE site observed that 17% of individuals with the
p.Cys282Tyr homozygous genotype were known to have
received oral iron, and one of these individuals developed
significant iron overload, possibly as a result of this medi-
cation. The finding of common use of iron supplementa-
tion in these individuals is not unexpected, given the gen-
eral frequency of iron supplementation. Had the HH
susceptibility of these individuals been known, iron sup-
plementation most likely would have been avoided or
more carefully monitored. Although not an original objec-
tive of the study, eMERGE sites capable of re-contact are
addressing the possible return of HH genotype results to
relevant individuals. For other sites, either data are de-
identified and re-contact is not possible or affected partic-
ipants are now deceased. Future prospective studies will
need to evaluate clinical outcomes in individuals identified
through preemptive diagnosis of hemochromatosis.
From a research perspective, another important implica-
tion from our study is that multicenter retrospective co-
hortsmight be useful for determining penetrance estimates
of inherited disorders. This idea is supported by the fact that
most of our penetrance estimates were consistent with
those from studies of prospective hemochromatosis co-
horts. Our findings could serve as a proof of concept that
linking genotypedata tomedical-record informationmight
be useful for estimating clinical penetrance of relatively un-
common genotypes associated with common diseases, for
example, the estimation of neurologic disease in individ-
uals harboring glucocerebrosidase (GBA [MIM: 606463])
variants, whichhave been found to cause Parkinson disease
in Ashkenazi Jews,28 or the contribution of BRCA1 (MIM:
113705) andBRCA2 (MIM: 600185) variants to thedevelop-
ment of breast cancer in the general population. Given that
several phenotypes could be studied under one cohort, this
might also represent a cost-effectivemethod for penetrance
estimation.an Journal of Human Genetics 97, 512–520, October 1, 2015 517
Our study has several major limitations. First, because
this was a retrospective cohort study collecting phenotype
and diagnosis data with chart abstractions, the data from
the pre-existing clinical records were incomplete. For
example, in many cases, imaging data, specific clinical
findings, and laboratory values sought for the chart
abstraction were not found in the clinical record (see Table
S3 for differences in the total number of individuals for
each variable). Some clinical sites, such as those with
health-maintenance-organization care models, had very
complete clinical records, whereas referral centers in gen-
eral had higher numbers of records missing the data we
sought for our purposes, which could have led to underes-
timation of penetrance. Alternatively, in many partici-
pants with a HH diagnosis, it was unclear which criteria
were used for diagnosis; it is possible that some of these
participants did not manifest HH signs or symptoms but
were genotyped specifically for HFE variants on the basis
of family history of this disorder instead of clinical presen-
tation and were incorrectly diagnosed with HH. Although
possible inclusion of participants with a HH family history
and predisposing genotype without clinical signs or symp-
toms might lead to overestimation of the HH diagnostic
rate, it does not lead to overestimation of the required clin-
ical care. It can be argued that even if a person lacking signs
and symptoms is clinically misdiagnosed with HH because
of a family history and genotype, the fact that the test was
done and a HH diagnosis was made would support the
advantage of opportunistic screening as opposed to clinical
screening. It also might be an opportunity for a geneticist
or other expert to clarify whether or not the individual is
indeed affected by HH.
A second limitation is the lack of a true control group
who did not have genotypes at risk for HH. This was due
to resource limitations for the chart reviews. Although
such a group was not necessary for evaluating diagnostic
rates, it would have been useful for determining the base-
line rate of the potential HH-related phenotypes, such as
liver disease that could not be attributed to HH. Because
we expected a lower rate of end-organ damage in the com-
pound heterozygotes, these provided a good comparison
to the p.Cys282Tyr homozygotes. The lower clinical and
biochemical penetrance of HH in compound heterozy-
gotes than in p.Cys282Tyr homozygous individuals has
been documented in large prospective studies, and our es-
timates were overall consistent with these estimates. For
example, in the Pedersen et al. study,25 a transferrin satura-
tion > 50% was found in 88.9% of p.Cys282Tyr homozy-
gotes and 22.7% of p.[Cys282Tyr];[His63Asp] compound
heterozygotes (in comparison to 100% and 37.5%, respec-
tively, in our study). In that same study, the penetrance
rate of this phenotype was 14.9% in p.His63Asp homozy-
gous individuals and 5.7% in HFE wild-types, confirming
the strong effect of genotype on biochemical penetrance.
The higher penetrance in p.Cys282Tyr homozygotes
than in compound heterozygotes, as well as the even lower
penetrance in p.His63Asp homozygotes and HFE wild-518 The American Journal of Human Genetics 97, 512–520, Octobertypes, has also been documented for clinical phenotypes,
including liver disease, fatigue, and arthritis.13 The disease
penetrance attributable to compound heterozygotes or
p.Cys282Tyr homozygotes when compared to individuals
with wild-type HFE or single p.Cys282Tyr or p.His63Asp
heterozygotes in multicenter cohorts with genotype data
linked to medical records will need to be determined by
future studies.
A third major limitation was heterogeneity in terms of
clinical sites and the subject selection, which was not
random when compared to the general population. Our
study collected data from seven sites, some of which ascer-
tained people from outpatient clinics (others recruited in
hospitals), and there was also heterogeneity in the pheno-
type selection. To address this limitation, we looked for po-
tential sources of confounding with the HH diagnosis and
the pleiotropic effect of iron overload. This concern was
mitigated by exclusion of participants ascertained in a liver
clinic and the exclusion of liver-biopsy data for those ascer-
tained because of gastric-bypass surgery with concurrent
routine liver biopsy.
A fourth limitation is that because of a lownumber of par-
ticipants from other races and ethnicities, our analysis was
restricted to individualsof Europeanancestry; thus, ourcon-
clusions cannot be generalized to other populations. Future
studies will be needed to address the question of clinical
penetrance of HH in non-Europeans, who have a consider-
ably lower frequency of HH-causing HFE variants.8
In summary, we evaluated the diagnostic rate and esti-
mated the penetrance of iron overload and associated organ
damage for the two most common HH genotypes in a
densely phenotyped cohort selected for reasons unassoci-
ated with HH. We found that the rate of HH diagnosis is
higher than previously reported and confirmed that the
prevalenceof ironoverload ishigher inHFEp.Cys282Tyrho-
mozygotes than in compoundheterozygotes.We also found
that, compared to large prospective cohorts, unselected
multicenter retrospective cohorts might be good models
for obtaining penetrance estimates. Theuse of opportunistic
screening for HFE p.Cys282Tyr homozygosity conferring
risk of HH in those with existing genomic data should be re-
considered in light of this and future evidence. Furthermore,
genetic testing in the general population should be evalu-
ated with studies of outcomes research and cost effective-
ness, especially considering the decreasing cost of
genomic-technology applications and the additive effective-
ness of assessing the risk for multiple adult-onset diseases.Supplemental Data
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